130 related articles for article (PubMed ID: 1590100)
1. Serum SHBG levels during normal menstrual cycle and after insertion of levonorgestrel-releasing IUD.
Jia MC; Zhou LY; Ren S; Dong L; Xiao B
Adv Contracept; 1992 Mar; 8(1):33-40. PubMed ID: 1590100
[TBL] [Abstract][Full Text] [Related]
2. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device.
Xiao BL; Zhou LY; Zhang XL; Jia MC; Luukkainen T; Allonen H
Contraception; 1990 Apr; 41(4):353-62. PubMed ID: 2335100
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
Heikinheimo O; Gordon K; Williams RF; Hodgen GD
Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
[TBL] [Abstract][Full Text] [Related]
5. Ovarian function after seven years' use of a levonorgestrel IUD.
Barbosa I; Olsson SE; Odlind V; Goncalves T; Coutinho E
Adv Contracept; 1995 Jun; 11(2):85-95. PubMed ID: 7491859
[TBL] [Abstract][Full Text] [Related]
6. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol.
Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A
Arch Gynecol Obstet; 1998; 261(4):201-8. PubMed ID: 9789651
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate.
Toddyvalla V; Johannisson E; Landgren BM; Cekan SZ; Diczfalusy E
Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
Kuhnz W; Staks T; Jütting G
Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
[TBL] [Abstract][Full Text] [Related]
9. Ovarian function during use of a levonorgestrel-releasing IUD.
Barbosa I; Bakos O; Olsson SE; Odlind V; Johansson ED
Contraception; 1990 Jul; 42(1):51-66. PubMed ID: 2117516
[TBL] [Abstract][Full Text] [Related]
10. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1.
Pakarinen P; Lähteenmäki P; Rutanen EM
Acta Obstet Gynecol Scand; 1999 May; 78(5):423-8. PubMed ID: 10326889
[TBL] [Abstract][Full Text] [Related]
11. The interaction between sex hormone binding globulin and levonorgestrel released from vaginal rings in women.
Cekan SZ; Jia M; Landgren BM; Diczfalusy E
Contraception; 1985 Apr; 31(4):431-9. PubMed ID: 3924477
[TBL] [Abstract][Full Text] [Related]
12. Sex hormone binding globulin and free levonorgestrel index in the first week after insertion of Norplant implants.
Alvarez F; Brache V; Tejada AS; Cochon L; Faundes A
Contraception; 1998 Oct; 58(4):211-4. PubMed ID: 9866001
[TBL] [Abstract][Full Text] [Related]
13. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
Suvisaari J; Lähteenmäki P
Contraception; 1996 Oct; 54(4):201-8. PubMed ID: 8922872
[TBL] [Abstract][Full Text] [Related]
14. Changes in physiologically free circulating estradiol and testosterone during exposure to levonorgestrel.
Stumpf PG; Nakamura RM; Mishell DR
J Clin Endocrinol Metab; 1981 Jan; 52(1):138-43. PubMed ID: 6778889
[TBL] [Abstract][Full Text] [Related]
15. Interrelationship of serum levonorgestrel and sex hormone-binding globulin levels following vaginal and oral administration of combined steroid contraceptive tablets.
Abdalla KA; Shabaan MM; Stanczyk FZ
Contraception; 1992 Feb; 45(2):111-8. PubMed ID: 1559334
[TBL] [Abstract][Full Text] [Related]
16. Effect of some oral contraceptives on serum concentrations of sex hormone binding globulin and ceruloplasmin.
Song S; Chen JK; He ML; Fotherby K
Contraception; 1989 Apr; 39(4):385-99. PubMed ID: 2498034
[TBL] [Abstract][Full Text] [Related]
17. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
Luukkainen T; Toivonen J
Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
[TBL] [Abstract][Full Text] [Related]
18. Sex hormone-binding globulin changes during the menstrual cycle.
Plymate SR; Moore DE; Cheng CY; Bardin CW; Southworth MB; Levinski MJ
J Clin Endocrinol Metab; 1985 Nov; 61(5):993-6. PubMed ID: 2413065
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
Kuhnz W; al-Yacoub G; Fuhrmeister A
Contraception; 1992 Nov; 46(5):455-69. PubMed ID: 1458892
[TBL] [Abstract][Full Text] [Related]
20. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Nestler JE; Powers LP; Matt DW; Steingold KA; Plymate SR; Rittmaster RS; Clore JN; Blackard WG
J Clin Endocrinol Metab; 1991 Jan; 72(1):83-9. PubMed ID: 1898744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
